title: Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment.
abstract: OBJECTIVE
  To evaluate medical and work disability costs for patients with chronic inflammatory joint disease during one year before and one year after institution of infliximab treatment in routine clinical practice.
  
  
  METHODS
  Starting from 1999, clinical and laboratory variables for patients treated with biological agents for inflammatory rheumatic diseases were systematically recorded at Helsinki University Central Hospital. From this database clinical information was collected on 96 patients in whom infliximab was started during the period 1999 to 2001. Economic analyses were based on costs incurred because of outpatient and inpatient visits, orthopaedic operations, drugs used, and days on sickness or rehabilitation allowance. Medical and work disability costs were calculated separately for the one year period before (period I) and the one year period after institution of infliximab (period II).
  
  
  RESULTS
  Of the study group of 96 patients (arthritis duration 16 years (range 3 to 43)), 74 completed one year of infliximab treatment. Their clinical and laboratory variables improved significantly. The mean increase in medical costs during period II was euro12 015 (95% confidence interval, 6496 to 18,076). A minimal decrease in work disability costs occurred-mean decrease euro130 (-1268 to 1072).
  
  
  CONCLUSIONS
  One year treatment with infliximab in patients with longstanding aggressive arthritis showed a good clinical effect but raised medical costs significantly. Work disability costs failed to show a substantial decrease. Starting infliximab in the earlier stages of chronic arthritis could in the long term prevent work disability and thus decrease the total cost to society.
authors.affiliation: Division of Rheumatology, Department of Medicine, Helsinki University Central Hospital, Kasarmikatu 11-13, PO Box 263, FIN-00029 HUS, Finland. karin.laas@helsinki.fi
authors.forename: K
authors.initials: K
authors.lastname: Laas
authors.forename: R
authors.initials: R
authors.lastname: Peltomaa
authors.forename: H
authors.initials: H
authors.lastname: Kautiainen
authors.forename: K
authors.initials: K
authors.lastname: Puolakka
authors.forename: M
authors.initials: M
authors.lastname: Leirisalo-Repo
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000191:economics* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000191:economics*; D017281:Cost of Illness; D003365:Costs and Cost Analysis; D016527:Drug Costs; D004359:Drug Therapy, Combination; D005260:Female; D005387:Finland; D005938:Glucocorticoids / Q000191:economics / Q000627:therapeutic use; D006760:Hospitalization / Q000191:economics; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D009819:Office Visits / Q000191:economics; D018434:Sickness Impact Profile; D014940:Work Schedule Tolerance
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D005938:Glucocorticoids; D000069285:Infliximab